Open Label, Phase I ZD6474 Head and Neck Cancer Study

An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma

The purpose of this study is to determine the maximum tolerated dose of ZD6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.

Inclusion Criteria:

• Stage III-IV squamous cell carcinoma of the head and neck

Exclusion Criteria:

• No previous treatment for head and neck cancer, adequate cardiac function